Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    Alzheimer's | DHA
Show Display Options
Rank Status Study
1 Completed
Has Results
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: DHA (Docosahexaenoic Acid);   Drug: Placebo
2 Completed Preliminary Study of Fish Oil and Dementia
Conditions: Alzheimer's Disease;   Mild Cognitive Impairment
Intervention: Dietary Supplement: omega-3 polyunsaturated fatty acids ( EPA+DHA)
3 Completed Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)
Condition: Early Onset Alzheimer Disease
Interventions: Dietary Supplement: Neptune Krill Oil;   Dietary Supplement: Fish Oil;   Dietary Supplement: Placebo (soy oil)
4 Completed Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?
Condition: Healthy
Intervention: Dietary Supplement: omega-3 fatty acids
5 Recruiting n-3 PUFA for Vascular Cognitive Aging
Conditions: Age Related Cognitive Decline;   Alzheimer's Disease;   Vascular Dementia;   Endothelial Dysfunction;   Executive Dysfunction
Interventions: Drug: Omega 3 PUFA;   Drug: Placebo
6 Completed Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline
Condition: Frail Elderly Subjects
Interventions: Dietary Supplement: omega-3;   Behavioral: multi-domain intervention;   Drug: Placebo
7 Completed Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?
Condition: Healthy
Intervention: Dietary Supplement: omega-3 fatty acid

Indicates status has not been verified in more than two years